|
1
|
Cosentino F, Grant PJ, Aboyans V, Bailey
CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE,
Hansen TB, et al: 2019 ESC Guidelines on diabetes, pre-diabetes,
and cardiovascular diseases developed in collaboration with the
EASD. Eur Heart J. 41:255–323. 2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Jia G, Whaley-Connell A and Sowers JR:
Diabetic cardiomyopathy: A hyperglycaemia and insulin
resistance-induced heart disease. Diabetologia. 61:21–28.
2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Lee JH, Budanov AV, Park EJ, Birse R, Kim
TE, Perkins GA, Ocorr K, Rllisman MH, Bodmer R, Bier E and Karin M:
Sestrin as a feedback inhibitor of TOR that prevents age-related
pathologies. Science. 327:1223–1228. 2010.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Gao A, Li F, Zhou Q and Chen L: Sestrin2
as a potential therapeutic target for cardiovascular diseases.
Pharmacol Res. 159(104990)2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Ding B, Parmigiani A, Divakaruni AS,
Archer K, Murphy AN and Budanov AV: Sestrin2 is induced by glucose
starvation via the unfolded protein response and protects cells
from non-canonical necroptotic cell death. Sci Rep.
6(2253)2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Livak KJ and Schmittgen TD: Analysis of
reactive gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Zhang X, Zhong Z and Li W: Downregulation
of TRAP1 aggravates injury of H9c2 cardiomyocytes in a
hyperglycemic state. Exp Ther Med. 18:2681–2686. 2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Federico M, Fuente S, Palomeque J and Sheu
S: The role of mitochondria in metabolic disease: A special
emphasis on heart dysfunction. J Physiol. 599:3477–3493.
2021.PubMed/NCBI View
Article : Google Scholar
|
|
9
|
Kubli D and Gustafsson Å: Unbreak my
heart: Targeting mitochondrial autophagy in diabetic
cardiomyopathy. Antioxid Redox Signal. 22:1527–1544.
2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Budanov AV, Lee JH and Karin M: Stressin
Sestrins take an aging fight. EMBO Mol Med. 2:388–400.
2010.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Sun W, Wang Y, Zheng Y and Quan N: The
emerging role of Sestrin2 in cell metabolism, and cardiovascular
and age-related diseases. Aging Dis. 11:154–163. 2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Quan N, Li X, Zhang J, Han Y, Sun W, Ren
D, Tong Q and Li J: Substrate metabolism regulated by
Sestrin2-mTORC1 alleviates pressure overload-induced cardiac
hypertrophy in aged heart. Redox Biol. 36(101637)2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Lee JH, Budanov AV, Talukdar S, Park EJ,
Park HL, Park HW, Bandyopadhyay G, Li N, Aghajan M, Jang I, et al:
Maintenance of metabolic homeostasis by Sestrin2 and Sestrin3. Cell
Metab. 16:311–321. 2012.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Lin Q, Ma Y, Chen Z, Hu J, Chen C, Fan Y,
Liang W and Ding G: Sestrin-2 regulates podocyte mitochondrial
dysfunction and apoptosis under high-glucose conditions via AMPK.
Int J Mol Med. 45:1361–1372. 2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Sundararajan S, Jayachandran I,
Balasubramanyam M, Mohan V, Venkatesan B and Manickam N: Sestrin2
regulates monocyte activation through AMPK-mTOR nexus under
high-glucose and dyslipidemic conditions. J Cell Biochem: Nov 18,
2018 (Epub ahead of print). doi: 10.1002/jcb.28102.
|
|
16
|
Hwang H, Kim JW, Chung HS, Seo JA, Kim SG,
Kim NH, Choi KM, Baik SH and Yoo HJ: Knockdown of Sestrin2
increases lipopolysaccharide-induced oxidative stress, apoptosis,
and fibrotic reactions in H9c2 cells and heart tissues of mice via
an AMPK-dependent mechanism. Mediators Inflamm.
2018(6209140)2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Dong B, Xue R, Sun Y, Dong Y and Liu C:
Sestrin 2 attenuates neonatal rat cardiomyocyte hypertrophy induced
by phenylephrine via inhibiting ERK1/2. Mol Cell Biochem.
433:113–123. 2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Budanov AV, Shoshani T, Faerman A, Zelin
E, Kamer I, Kalinski H, Gorodin S, Fishman A, Chajut A, Einat P, et
al: Identification of a novel stress-responsive gene Hi95 involved
in regulation of cell viability. Oncogene. 21:6017–6031.
2002.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Wang H, Li N, Shao X, Li J, Guo L, Yu X,
Sun Y, Hao J, Xiang J, Li X and Han X: Increased plasma sestrin2
concentrations in patients with chronic heart failure and predicted
the occurrence of major adverse cardiac events: A 36-month
follow-up cohort study. Clin Chim Acta. 495:338–344.
2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Kishimoto Y, Aoyama M, Saita E, Ikegami Y,
Ohmori R, Kondo K and Momiyama Y: Association between plasma
Sestrin2 Levels and the presence and severity of coronary artery
disease. Dis Markers. 2020(7439574)2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Kishimoto Y, Saita E, Ohmori R, Kondo K
and Momiyama Y: Plasma sestrin2 concentrations and carotid
atherosclerosis. Clin Chim Acta. 504:56–59. 2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Chung HS, Hwang H, Hwang SY, Kim NH, Seo
JA, Kim SG, Kim NH, Sei Baik H, Choi KM and Yoo HJ: Association of
serum Sestrin2 level with metabolic risk factors in newly diagnosed
drug-naïve type 2 diabetes. Diabetes Res Clin Pract. 144:34–41.
2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Sundararajan S, Jayachandran I,
Subramanian SC, Anjana RM, Balasubramanyam M, Mohan V, Venkatesan B
and Manickam N: Decreased Sestrin levels in patients with type 2
diabetes and dyslipidemia and their association with the severity
of atherogenic index. J Endocrinol Invest. 44:1395–1405.
2021.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Mohany KM and Rugaie OA: Association of
serum sestrin 2 and betatrophin with serum neutrophil gelatinase
associated lipocalin levels in type 2 diabetic patients with
diabetic nephropathy. J Diabetes Metab Disord. 19:249–256.
2020.PubMed/NCBI View Article : Google Scholar
|
